Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC

NACompletedINTERVENTIONAL
Enrollment

235

Participants

Timeline

Start Date

June 30, 2017

Primary Completion Date

April 30, 2021

Study Completion Date

January 30, 2023

Conditions
Small Cell Lung Cancer Limited StageRadiotherapy
Interventions
RADIATION

SIB

patients will recieve twice-daily radiotherapy by simultaneous integrated boosting technique concurrent with chemotherapy

RADIATION

Standard

patients will recieve standard twice-daily radiotherapy concurrent with chemotherapy

Trial Locations (1)

Unknown

Beijing Cancer Hospital, Beijing

All Listed Sponsors
collaborator

Sun Yat-sen University

OTHER

collaborator

Fudan University

OTHER

collaborator

Xijing Hospital

OTHER

collaborator

Henan Cancer Hospital

OTHER_GOV

collaborator

Jilin Provincial Tumor Hospital

OTHER

collaborator

First Affiliated Hospital of Xinjiang Medical University

OTHER

collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

collaborator

Air Force General Hospital of the PLA

OTHER_GOV

collaborator

China-Japan Friendship Hospital

OTHER

collaborator

Peking University Third Hospital

OTHER

collaborator

Peking Union Medical College Hospital

OTHER

collaborator

Beijing Hospital

OTHER_GOV

collaborator

Beijing Chao Yang Hospital

OTHER

collaborator

Peking University People's Hospital

OTHER

collaborator

Peking University First Hospital

OTHER

lead

Anhui Shi, MD

OTHER

NCT03214003 - Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC | Biotech Hunter | Biotech Hunter